The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl

[1]  A. Ashkenazi.  Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. , 2015, The Journal of clinical investigation.

[2]  S. Marsters,et al.  E-cadherin couples death receptors to the cytoskeleton to regulate apoptosis. , 2014, Molecular cell.

[3]  T. D’alfonso,et al.  Axl receptor tyrosine kinase expression in breast cancer , 2014, Journal of Clinical Pathology.

[4]  J. von Pawel,et al.  Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. , 2014, Clinical lung cancer.

[5]  P. Holland.  Death receptor agonist therapies for cancer, which is the right TRAIL? , 2014, Cytokine & growth factor reviews.

[6]  G. Tse,et al.  P-cadherin and vimentin are useful basal markers in breast cancers. , 2013, Human pathology.

[7]  Jun Hong,et al.  AXL mediates TRAIL resistance in esophageal adenocarcinoma. , 2013, Neoplasia.

[8]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[9]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[10]  S. Lipkowitz,et al.  WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis , 2011, Molecular Cancer Research.

[11]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[12]  A. Yang,et al.  An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. , 2011, Cancer cell.

[13]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[14]  K. Hess,et al.  DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. , 2011, The oncologist.

[15]  J. Vose,et al.  A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma , 2010, British Journal of Cancer.

[16]  Charles M Perou,et al.  Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.

[17]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[18]  J. L. Costa,et al.  P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study. , 2010, Histology and histopathology.

[19]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Herbst,et al.  A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies , 2010, Clinical Cancer Research.

[21]  V. Heinemann,et al.  Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer , 2010, British Journal of Cancer.

[22]  S. Lipkowitz,et al.  Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. , 2010, Breast disease.

[23]  N. Caplen,et al.  Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome , 2010, Breast Cancer Research and Treatment.

[24]  J. Pumphrey,et al.  The TRAIL to targeted therapy of breast cancer. , 2009, Advances in cancer research.

[25]  P. Meltzer,et al.  TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype , 2008, Breast Cancer Research and Treatment.

[26]  D. Lawrence,et al.  Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 , 2008, Cell Death and Differentiation.

[27]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[28]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[29]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patients , 2007, Cancer.

[30]  B. Rubino,et al.  The role of epithelial-mesenchymal transition in cancer pathology. , 2007, Pathology.

[31]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[32]  J. Benítez,et al.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas , 2006, Journal of Clinical Pathology.

[33]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[34]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[35]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[36]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[37]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  L. Holmberg,et al.  Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts , 2005, Breast Cancer Research.

[39]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Rosenberg,et al.  Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute SEER database , 2005 .

[41]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[42]  Z. Gatalica,et al.  Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. , 2003, American journal of clinical pathology.

[43]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[44]  F. Meric,et al.  Expression profile of tyrosine kinases in breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  E. Dreher,et al.  Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[47]  Emad S. Alnemri,et al.  Temperature-sensitive Differential Affinity of TRAIL for Its Receptors , 2000, The Journal of Biological Chemistry.

[48]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[49]  M. Nau,et al.  Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. , 1999, Cancer research.

[50]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[51]  G M Cohen,et al.  Caspases: the executioners of apoptosis. , 1997, The Biochemical journal.

[52]  G. Shah,et al.  Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. , 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.